These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10582540)

  • 1. Verapamil acute administration: a new dynamic test in hyperprolactinemic states.
    Barbaro D; Faggionato F; Pallini S; Carnesecchi C; Palla A; Bombara M; Falciani C; La Gioia A; Loni G
    Metabolism; 1999 Nov; 48(11):1351-6. PubMed ID: 10582540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia.
    Knoepfelmacher M; Villares SM; Nicolau W; Germek OO; Lerário AC; Wajchenberg BL; Liberman B
    Horm Metab Res; 1994 Oct; 26(10):481-5. PubMed ID: 7851873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects.
    Sarnacchiaro F; Colao A; Merola B; Di Sarno A; Landi ML; Di Somma C; Ferone D; Tolino A; Lombardi G
    J Endocrinol Invest; 1997 Oct; 20(9):513-8. PubMed ID: 9413804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
    Lissoni P; Mainini E; Mazzi C; Cattaneo G; Barni S
    J Endocrinol Invest; 1990 Feb; 13(2):85-9. PubMed ID: 2329263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma.
    Dombrowski RC; Romeo JH; Aron DC
    Ann Pharmacother; 1995 Oct; 29(10):999-1001. PubMed ID: 8845563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia.
    Kelley SR; Kamal TJ; Molitch ME
    Am J Physiol; 1996 Jan; 270(1 Pt 1):E96-100. PubMed ID: 8772480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients.
    Muratori M; Romano C; Gambino G; Faglia G
    Horm Res; 1994; 42(6):257-61. PubMed ID: 7698720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?
    Di Sarno A; Rota F; Auriemma R; De Martino MC; Lombardi G; Colao A
    J Endocrinol Invest; 2003; 26(7 Suppl):39-47. PubMed ID: 14604065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macroprolactinaemia associated with prolactin adenoma.
    Mounier C; Trouillas J; Claustrat B; Duthel R; Estour B
    Hum Reprod; 2003 Apr; 18(4):853-7. PubMed ID: 12660284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of hypothalamic hyperprolactinemia.
    Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
    J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of calcium infusion on serum prolactin in hyperprolactinemic women.
    Yildiz L; Uyanik BS; Kuşkay S; Küçük M
    J Basic Clin Physiol Pharmacol; 1995; 6(3-4):303-7. PubMed ID: 8852276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Verapamil-induced hyperprolactinemia--a case report].
    Krysiak R; Okopieh B; Herman ZS
    Pol Arch Med Wewn; 2005 Feb; 113(2):155-8. PubMed ID: 16209236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc does not acutely suppress prolactin in normal or hyperprolactinemic women.
    Koppelman MC; Greenwood V; Sohn J; Deuster P
    J Clin Endocrinol Metab; 1989 Jan; 68(1):215-8. PubMed ID: 2491863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and pitfalls in the diagnosis of hyperprolactinemia.
    Vilar L; Fleseriu M; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):9-22. PubMed ID: 24728159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased androgen secretion in patients with prolactinomas: the impact of altered HPA function.
    Moria Y; Kortbawi R; El-Asmar N; Arafah BM
    Pituitary; 2019 Apr; 22(2):170-178. PubMed ID: 30798438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etiological diagnosis of hyperprolactinemia.
    Cortet-Rudelli C; Sapin R; Bonneville JF; Brue T
    Ann Endocrinol (Paris); 2007 Jun; 68(2-3):98-105. PubMed ID: 17524347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of prolactin secretion.
    Benker G; Jaspers C; Häusler G; Reinwein D
    Klin Wochenschr; 1990 Dec; 68(23):1157-67. PubMed ID: 2126309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.
    Dagdelen S; Usman A
    Minerva Endocrinol; 2010 Jun; 35(2):53-9. PubMed ID: 20595935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.